Bruker Corporation (NASDAQ:BRKR) Receives Average Recommendation of “Hold” from Analysts

Shares of Bruker Corporation (NASDAQ:BRKR) have received a consensus recommendation of “Hold” from the fifteen brokerages that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $49.3846.

Several equities analysts recently commented on BRKR shares. Citigroup dropped their target price on Bruker from $53.00 to $40.00 and set a “neutral” rating for the company in a research note on Friday, February 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research note on Friday, March 27th. Barclays dropped their price target on Bruker from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Guggenheim dropped their price target on Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Finally, UBS Group restated a “neutral” rating and set a $49.00 price target on shares of Bruker in a research note on Friday, February 13th.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at $5,124,875.70. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 27.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bruker

A number of large investors have recently modified their holdings of BRKR. Los Angeles Capital Management LLC acquired a new stake in shares of Bruker in the fourth quarter valued at about $26,000. Allworth Financial LP grew its stake in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Parallel Advisors LLC grew its stake in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares in the last quarter. Spire Wealth Management grew its stake in shares of Bruker by 85.3% in the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after buying an additional 665 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new stake in shares of Bruker in the fourth quarter valued at about $50,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Performance

Bruker stock opened at $40.09 on Friday. The firm has a market capitalization of $6.10 billion, a P/E ratio of -267.27, a PEG ratio of 2.46 and a beta of 1.20. The stock has a fifty day moving average price of $37.40 and a 200 day moving average price of $41.93. Bruker has a 52 week low of $28.53 and a 52 week high of $56.22. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). The business had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts anticipate that Bruker will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were paid a dividend of $0.05 per share. The ex-dividend date was Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s dividend payout ratio is currently -133.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.